Search research articles
Contact Us
Filters
Showing results (51-60 of 87) with videos related to
Page
of 9
Sort By:
Methods of Information in Medicine
|
April 17, 2025
Automated Information Extraction from Unstructured Hematopathology Reports to Support Response Assessment in Myeloproliferative Neoplasms
Spencer Krichevsky, Evan T Sholle, Prakash M Adekkanattu, et al.
Transplantation and Cellular Therapy
|
September 7, 2024
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors)
Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, et al.
The Lancet. Haematology
|
March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
American Journal of Hematology
|
March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The Lancet. Haematology
|
June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
Michele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Haematologica
|
May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Kathryn E Flynn, Ehab Atallah, Li Lin, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
October 8, 2019
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension
Jiwon Kim, Spencer Krichevsky, Lola Xie, et al.
Blood
|
August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
Oliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 87) with videos related to
Sort By:
Page
of 9
Methods of Information in Medicine
|
April 17, 2025
Automated Information Extraction from Unstructured Hematopathology Reports to Support Response Assessment in Myeloproliferative Neoplasms
Spencer Krichevsky, Evan T Sholle, Prakash M Adekkanattu, et al.
Transplantation and Cellular Therapy
|
September 7, 2024
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors)
Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, et al.
The Lancet. Haematology
|
March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
American Journal of Hematology
|
March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The Lancet. Haematology
|
June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
Michele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Haematologica
|
May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Kathryn E Flynn, Ehab Atallah, Li Lin, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
October 8, 2019
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension
Jiwon Kim, Spencer Krichevsky, Lola Xie, et al.
Blood
|
August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
Oliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Page
of 9